UroGen Pharma Ltd. Employee-related Liabilities, Current
UroGen Pharma Ltd. (URGN) had Employee-related Liabilities, Current of $12.25 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:EmployeeRelatedLiabilitiesCurrent · last filed 2026-08-05
- 2026-06-30: Employee-related Liabilities, Current $12.25M.
- 2026-03-31: Employee-related Liabilities, Current $9.84M.
- 2025-12-31: Employee-related Liabilities, Current $13.52M.
- 2025-09-30: Employee-related Liabilities, Current $11.11M.
| Period end | Employee-related Liabilities, Current |
|---|---|
| 2026-06-30 | $12.25M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $9.84M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $13.52M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $11.11M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $11.65M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $6.97M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $10.57M 10-K · filed 2026-03-02 |
| 2024-09-30 | $9.03M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $6.85M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $4.99M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $10.81M 10-K · filed 2025-03-10 |
| 2023-09-30 | $8.15M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $6.72M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $4.92M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $8.26M 10-K · filed 2024-03-14 |
| 2022-09-30 | $6.63M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $6.43M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $5.15M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $6.95M 10-K · filed 2023-03-24 |
| 2021-09-30 | $6.48M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $6.77M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $4.71M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $9.55M 10-K · filed 2022-03-21 |
| 2020-09-30 | $7.79M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $5.74M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $4.08M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $6.71M 10-K · filed 2021-03-18 |
| 2019-09-30 | $5.08M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $3.71M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $3.33M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $4.92M 10-K · filed 2020-03-02 |
| 2018-09-30 | $2.68M 6-K · filed 2018-11-13 |
| 2018-06-30 | $2.21M 6-K · filed 2018-08-14 |
| 2018-03-31 | $1.29M 6-K · filed 2018-05-15 |
| 2017-12-31 | $1.95M 10-K · filed 2019-02-28 |
| 2016-12-31 | $687.00K 20-F · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |